238 related articles for article (PubMed ID: 11139058)
1. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
3. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
4. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
5. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
[TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
7. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
Muratet JP; Daver A; Minier JF; Larra F
J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
[TBL] [Abstract][Full Text] [Related]
8. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours.
Gerard SK; Cavalieri RR
Clin Nucl Med; 2002 Jan; 27(1):1-8. PubMed ID: 11805475
[TBL] [Abstract][Full Text] [Related]
9. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
11. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
[TBL] [Abstract][Full Text] [Related]
12. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
14. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
Gerard SK; Dam HQ
Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
[No Abstract] [Full Text] [Related]
15. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
[TBL] [Abstract][Full Text] [Related]
16. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.
Lin JD; Chao TC; Huang MJ; Weng HF; Tzen KY
Am J Clin Oncol; 1998 Feb; 21(1):77-81. PubMed ID: 9499265
[TBL] [Abstract][Full Text] [Related]
17. [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].
Gómez Camarero P; Martínez Brocca MA; Rodríguez Rodríguez JR; Navarro González E; Tirado Hospital JL; González Duarte D; Vázquez Albertino R; Astorga Jimenez R
Rev Esp Med Nucl; 2003; 22(5):295-305. PubMed ID: 14534005
[TBL] [Abstract][Full Text] [Related]
18. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
[TBL] [Abstract][Full Text] [Related]
19. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
20. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]